Acalabrutinib, is an experimental anti-cancer drug and a selective Brutons tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL). Synonyms: 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1- yl]-N-2-pyridinylbenzamide, ACP 196 CAS No: 1420477-60-6 Molecular Formula: C26H23N7O2 Molecular Weight: 465.51 Purity (HPLC): 98% Appearance: Light yellow to yellow solid Solubility: DMSO (Slightly), Methanol (Slightly) NMR, CNMR, LC-MS: Conforms to reference Storage and Stability: May be stored at RT for short-term only. Long-term storage is recommended at 4C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Molekulargewicht:
465.51
CAS Nummer:
[1420477-60-6]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
